White Square Capital’s Cardlytics CDLX Stock Holding History

White Square Capital’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-637	Closed	-$909K	–	17
2020 Q4	$909K	Buy	+637	New	+$679K	1.28%	30

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.88B AUM 2.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ACM

Alua Capital Management New York $103M AUM 11.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

White Square Capital's CDLX Position: Q1 2021 in Review

White Square Capital sold out of Cardlytics (CDLX) in Q1 2021, closing a stake of 637 shares — an estimated $909K sold.

White Square Capital first reported a position in CDLX in Q4 2020 and held it in 1 quarter. The position peaked at $909K in Q4 2020. 204 funds tracked by Wall St. Rank hold CDLX as of Q1 2021.

White Square Capital reported no remaining Cardlytics position as of Q1 2021 after selling out during the quarter.
White Square Capital sold 637 Cardlytics shares in Q1 2021, an estimated $909K.
White Square Capital first reported a position in Cardlytics in Q4 2020 and held it in 1 quarter.
White Square Capital's Cardlytics position peaked at $909K in Q4 2020.
204 funds tracked by Wall St. Rank held Cardlytics as of Q1 2021.

Based on White Square Capital's 13F filing for Q1 2021, filed 14 May 2021.